Group One Trading’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,334
| Closed | -$5K | – | 8385 |
|
|
2022
Q3 | $5K | Buy |
+2,334
| New | +$8.27K | ﹤0.01% | 6879 |
|
|
2022
Q2 | – | Sell |
-2,250
| Closed | -$10.9K | – | 8799 |
|
|
2022
Q1 | $15K | Sell |
2,250
-10,428
| -82% | -$74.3K | ﹤0.01% | 6974 |
|
|
2021
Q4 | $106K | Buy |
12,678
+8,400
| +196% | +$69.2K | ﹤0.01% | 5688 |
|
|
2021
Q3 | $32K | Buy |
4,278
+2,500
| +141% | +$15.5K | ﹤0.01% | 6891 |
|
|
2021
Q2 | $12K | Sell |
1,778
-2,350
| -57% | -$19.5K | ﹤0.01% | 7469 |
|
|
2021
Q1 | $42K | Buy |
+4,128
| New | +$45.2K | ﹤0.01% | 6353 |
|
|
2020
Q3 | – | Sell |
-3,760
| Closed | -$23.3K | – | 6703 |
|
|
2020
Q2 | $26K | Sell |
3,760
-3,601
| -49% | -$19.4K | ﹤0.01% | 4716 |
|
|
2020
Q1 | $35K | Sell |
7,361
-5,834
| -44% | -$33.6K | ﹤0.01% | 3944 |
|
|
2019
Q4 | $115K | Buy |
13,195
+10,954
| +489% | +$59.2K | ﹤0.01% | 3556 |
|
|
2019
Q3 | $7K | Sell |
2,241
-2,366
| -51% | -$9.47K | ﹤0.01% | 4696 |
|
|
2019
Q2 | $23K | Sell |
4,607
-12,040
| -72% | -$63.9K | ﹤0.01% | 4129 |
|
|
2019
Q1 | $103K | Buy |
16,647
+16,468
| +9,200% | +$79.6K | ﹤0.01% | 3155 |
|
|
2018
Q4 | $1K | Sell |
179
-42,300
| -100% | -$198K | ﹤0.01% | 4763 |
|
|
2018
Q3 | $276K | Buy |
+42,479
| New | +$316K | ﹤0.01% | 2770 |
|
|
2018
Q1 | – | Sell |
-568
| Closed | -$12.6K | – | 5446 |
|
|
2017
Q4 | $7K | Buy |
+568
| New | +$8.35K | ﹤0.01% | 4491 |
|
Other funds holding JNCE
Group One Trading's JNCE Position: Q4 2022 in Review
Group One Trading sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 2,334 shares — an estimated $5K sold.
Group One Trading first reported a position in JNCE in Q4 2017 and held it in 15 quarters. The position peaked at $276K in Q3 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.
- Group One Trading reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Group One Trading sold 2,334 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $5K.
- Group One Trading first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
- Group One Trading's Jounce Therapeutics, Inc. Common Stock position peaked at $276K in Q3 2018.
- 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.